Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.42) per share. This is a 93.01 percent increase over losses of $(6.01) per share from the same period last year.
Baird Downgrades Asana to Neutral, Lowers Price Target to $15
Baird analyst Rob Oliver downgrades Asana (NYSE:ASAN) from Outperform to Neutral and lowers the price target from $32 to $15.